Swish-e home page Search Rutgers Law Library N.J. Court Opinions


Limit search to:
Sort by:
Limit to:
    through    
 Results for ("N.J.S.A. 2a:58c-4")   16 to 30 of 55 results. Run time: 0.845 seconds | Search time: 0.839 seconds    
 Page:1 2 3 4 Previous 15 Next 15
16 ROBERT ROWE v. HOFFMANN-LA ROCHE INC., et al. -- rank: 817
... a contrary provision of New Jersey's Products Liability Act, N.J.S.A. 2A:58C-4. We conclude that New Jersey products liability law respecting the ... presumption shall arise that the warning or instruction is adequate. [ N.J.S.A. 2A:58C-4 (internal citations omitted) (emphasis added).] Thus the presumption under New ... New Jersey's interest in applying the rebuttable presumption of N.J.S.A. 2A:58C-4. Rowe cites what he describes as the New Jersey Supreme ... to New Jersey's interest expressed in the enactment of N.J.S.A. 2A:58C-4 as part of the Products Liability Act. In enacting the ... the appropriate level of protection each should be afforded. See N.J.S.A. 2A:58C-4. The Legislature determined that FDA approval of a drug's ... action is governed by New Jersey product liability law, specifically N.J.S.A. 2A:58C-4, which creates a rebuttable presumption that a drug warning ...
docket: a4522-03
court: njappellate
decided: 2006-02-28
status: published
citation: *CITE_PENDING*
Document Size: 67577
17 In Re: Reglan Litigation -- rank: 817
... and the ordinary knowledge common to, the prescribing physician.” N.J.S.A. 2A:58C-4. The Legislature recognized the important role of the federal regulatory ... into account . . . knowledge common to[] [a] prescribing physician.” See N.J.S.A. 2A:58C-4. Plaintiffs therefore must demonstrate that a reasonably prudent generic manufacturer ...
docket: a-56-14
court: New Jersey Supreme Court
decided: 2016-04-11
status:
citation:
Document Size: 95381
18 Tomeo v. Thomas Whitesell Construction Co., Inc. -- rank: 805
... were adequate regardless of whether plaintiff recalls seeing them. See N.J.S.A. 2A:58C-4. Nonetheless, he inserted his hand into the chute, not once ...
docket: a-25-02
court: njsupreme
decided: 2003-05-22
status:
citation: 176 N.J. 366
Document Size: 69831
19 DONALD MATHEWS v. UNIVERSITY LOFT CO. -- rank: 802
... warn if the product contains an adequate warning or instruction...." N.J.S.A. 2A:58C-4. The PLA defines "adequate product warning" in Section 4. Warnings ... Toxic Torts Law , § 6:3-1 at 69, but N.J.S.A. 2A:58C-4 defines what constitutes an "adequate product warning." It provides in ... persons by whom the product is intended to be used.... [ N.J.S.A. 2A:58C-4.] Hence, if under those standards, no warning is adequate, none ... a factor to establish what is an 'adequate warning' under N.J.S.A. 2A:58C-4, or whether a breach of that duty could be a ... 58C-3 entitled "Defenses," relates to design defect cases, while N.J.S.A. 2A:58C-4, entitled "Adequate product warning or instruction; rebuttable presumption of adequacy ...
docket: A1536-04
court: NJ Superior Court Appellate Division
decided: 2006-08-15
status: published
citation:
Document Size: 61642
20 ZAZA v. MARQUES AND NELL, INC. -- rank: 802
... the product is intended to be used. . .," would have acted. N.J.S.A. 2A:58C-4. Even if defendant wanted to provide a warning, there is ... defines the standard for determining the adequacy of the warning. N.J.S.A. 2A:58C-4. The Act must be read in conjunction with decisional law ... common law risk-utility factors and the affirmative defense under N.J.S.A. 2A:58C-4. In Michalko , this Court stated that "when it is feasible ... persons by whom the product is intended to be used." N.J.S.A. 2A:58C-4. Second, the Act did not intend to change the existing ...
docket: a-63-95
court: njsupreme
decided: 1996-05-09
status:
citation: 144 N.J. 34
Document Size: 101932
21 JOHN SCOTT CAMPAGNA, et al. v. AMERICAN CYANAMID COMPANY, -- rank: 796
... plaintiffs had failed to overcome the rebuttable presumption contained in N.J.S.A. 2A:58C-4, that a warning or instruction is adequate if approved by ... failure-to-warn claim, the motion judge correctly noted that N.J.S.A. 2A:58C-4 provides the framework for a manufacturer's duty to warn ... of, and the ordinary knowledge common to, the prescribing physician." N.J.S.A. 2A:58C-4. Implicit within Dr. Szumski's deposition testimony is the proposition ... warning statement on defendant's package insert was inadequate under N.J.S.A. 2A:58C-4 because it incorrectly specified that Orimune OPV was produced in ...
docket: A0695-99
court: NJ Superior Court Appellate Division
decided: 2001-03-05
status: published
citation: 337 N.J. Super. 530
Document Size: 50275
22 Robert Rowe v. Hoffman-La Roche, Inc. -- rank: 796
... labeling were approved by the FDA. New Jerseys statute, N.J.S.A. 2A:58C-4, provides that FDA approval creates only a rebuttable presumption that ... approval to have created only a rebuttable presumption of adequacy. N.J.S.A. 2A:58C-4. Thus, plaintiffs suit is viable in New Jersey but ... presumption shall arise that the warning or instruction is adequate. [ N.J.S.A. 2A:58C-4.] The Michigan statute thus creates a conclusive presumption that the ... and undervalued Michigans. The New Jersey statute at issue, N.J.S.A. 2A:58C-4, was enacted in 1987 as part of the New Jersey ... an award of punitive damages in products liability actions. See N.J.S.A. 2A:58C-4, cede to FDA regulation some of this States interest ... presumption shall arise that the warning or instruction is adequate. N.J.S.A. 2A:58C-4. Although our Legislature has precluded punitive damages by virtue ...
docket: a-19-06
court: njsupreme
decided: 2007-03-29
status:
citation: 189 N.J. 615
Document Size: 69909
23 Kamie S. Kendall v. Hoffman-LaRoche, Inc. -- rank: 787
... certif. denied, 188 N.J. 577 (2006). In that connection, N.J.S.A. 2A:58C-4 provides: In any product liability action the manufacturer or seller ... presumption shall arise that the warning or instruction is adequate. [ N.J.S.A. 2A:58C-4 (emphasis added).] Compliance with FDA regulations provides compelling, although not ... Further, in “rebalancing” the law in favor of manufacturers, N.J.S.A. 2A:58C-4 establishes that a product manufacturer “shall not be liable ... has been timely filed, that the statutory presumption contained in N.J.S.A. 2A:58C-4, which presumes FDA- approved labels are adequate, can be overcome ... analytical justification for according the statutory presumption set forth in N.J.S.A. 2A:58C-4 to “re-balance the law ‘in favor of ...
docket: A-73-10
court: NJ Supreme Court
decided: 2012-02-27
status:
citation: 209 N.J. 173 36 A.3d 541
Document Size: 65788
24 KATHLEEN ROSSITTO v. HOFFMAN-LA ROCHE INC -- rank: 771
... of, and the ordinary knowledge common to, the prescribing physician. [ N.J.S.A. 2A:58C-4.] Following FDA approval, a manufacturer has a continuing duty to ... presumption shall arise that the warning or instruction is adequate . [ N.J.S.A. 2A:58C-4 (emphasis added).] "Compliance with FDA regulations provides compelling, although not ... rebuttable presumption of adequacy that flows from FDA approval under N.J.S.A. 2A:58C-4. We previously rejected Roche's categorical argument on this issue ...
docket: a1236-13
court: NJ Superior Court Appellate Division
decided: 2016-07-22
status: unpublished
citation:
Document Size: 130302
25 LANCESAGER v. HOFFMAN-LA ROCHE, INC. -- rank: 753
... the sufficiency of the FDA-approved warning, as reflected in N.J.S.A. 2A:58C-4, is a pertinent but not dispositive factor in evaluating the ... the presumption of adequacy of an FDA-approved warning, see N.J.S.A. 2A:58C-4, in determining whether to apply equitable tolling principles. Kendall, supra ... the Court held that a trial judge may consider the N.J.S.A. 2A:58C-4 presumption of adequacy of an FDA-approved warning in determining ... defending belatedly-filed product liability lawsuits.' Further, the gravamen of N.J.S.A. 2A:58C-4 is that an FDA-approved label is presumably adequate to ... Inc., 540 So. 2d 102, 104 (Fla. 1989); see also N.J.S.A. 2A:58C-4; Perez, supra, 161 N.J. at 10 (1999); Restatement (Third ...
docket: A-3428-09
court: NJ Superior Court Appellate Division
decided: 2012-08-07
status: unpublished
citation:
Document Size: 153972
26 KAMIE S. KENDALL v. HOFFMAN-LA ROCHE, INC. -- rank: 746
... law. In New Jersey, that rebuttable presumption is codified at N.J.S.A. 2A:58C-4, a provision within our State's Product Liability Act ("PLA ... meanings defined in the "Federal Food, Drug, and Cosmetic Act." [ N.J.S.A. 2A:58C-4 (emphasis added).] When it adopted the PLA in 1987, the ...
docket: a2633-08
court: superior court appellate division
decided: 2005-12-21
status: unpublished
citation:
Document Size: 219553
27 GILLIAN GAGHAN v. HOFFMAN-LA ROCHE INC -- rank: 746
... Restatement (Third) of Torts: Products Liability , §6(d) (1998); N.J.S.A. 2A:58C-4; Perez v. Wyeth Labs., Inc. , 161 N.J. 1 , 10 ... be measured from the doctor's point of view. Cf. N.J.S.A. 2A:58C-4 ("An adequate product warning or instruction is one that a ... the presumption of adequacy of an FDA-approved warning under N.J.S.A. 2A:58C-4 in determining whether to apply equitable tolling principles to extend ...
docket: a3211-11
court: NJ Superior Court Appellate Division
decided: 2014-08-04
status: unpublished
citation:
Document Size: 105537
28 GILLIAN GAGHAN v. HOFFMAN-LA ROCHE INC -- rank: 746
... Restatement (Third) of Torts: Products Liability , §6(d) (1998); N.J.S.A. 2A:58C-4; Perez v. Wyeth Labs., Inc. , 161 N.J. 1 , 10 ... be measured from the doctor's point of view. Cf. N.J.S.A. 2A:58C-4 ("An adequate product warning or instruction is one that a ... the presumption of adequacy of an FDA-approved warning under N.J.S.A. 2A:58C-4 in determining whether to apply equitable tolling principles to extend ...
docket: a2717-11
court: NJ Superior Court Appellate Division
decided: 2014-08-04
status: unpublished
citation:
Document Size: 105537
29 GILLIAN GAGHAN v. HOFFMAN-LA ROCHE INC -- rank: 746
... Restatement (Third) of Torts: Products Liability , §6(d) (1998); N.J.S.A. 2A:58C-4; Perez v. Wyeth Labs., Inc. , 161 N.J. 1 , 10 ... be measured from the doctor's point of view. Cf. N.J.S.A. 2A:58C-4 ("An adequate product warning or instruction is one that a ... the presumption of adequacy of an FDA-approved warning under N.J.S.A. 2A:58C-4 in determining whether to apply equitable tolling principles to extend ...
docket: a3217-11
court: NJ Superior Court Appellate Division
decided: 2014-08-04
status: unpublished
citation:
Document Size: 105537
30 CATHY A. LONDON V. LEDERLE LABORATORIES AND E.R. SQUIBB & SONS -- rank: 737
... is no requirement that the manufacturer warn the patient herself. N.J.S.A. 2A:58C-4. The plaintiff in a product defect case also has the ...
docket: a6471-93
court: njappellate
decided: 1996-04-30
status: published
citation: 290 N.J.Super. 318
Document Size: 41572
 Page:1 2 3 4 Previous 15 Next 15
Powered by Swish-e swish-e.org

Valid HTML 4.01!